Current practices in hepatic artery infusion (HAI) chemotherapy: An international survey of the HAI Consortium Research Network Journal Article

   


Authors: Judge, S. J.; Ghalambor, T.; Cavnar, M. J.; Lidsky, M. E.; Merkow, R. P.; Cho, M.; Dominguez-Rosado, I.; Karanicolas, P. J.; Mayo, S. C.; Rocha, F. G.; Fields, R. C.; Patel, R. A.; Kennecke, H. F.; Koerkamp, B. G.; Yopp, A. C.; Petrowsky, H.; Mahalingam, D.; Kemeny, N.; D’Angelica, M.; Gholami, S.
Article Title: Current practices in hepatic artery infusion (HAI) chemotherapy: An international survey of the HAI Consortium Research Network
Abstract: Background: An increasing number of hepatic artery infusion (HAI) programs have been established worldwide. Practice patterns for this complex therapy across these programs have not been reported. This survey aimed to identify current practice patterns in HAI therapy with the long-term goal of defining best practices and performing prospective studies. Methods: Using SurveyMonkeyTM, a 28-question survey assessing current practices in HAI was developed by 12 HAI Consortium Research Network (HCRN) surgical oncologists. Content analysis was used to code textual responses, and the frequency of categories was calculated. Scores for rank-order questions were generated by calculating average ranking for each answer choice. Results: Thirty-six (72%) HCRN members responded to the survey. The most common intended initial indications for HAI at new programs were unresectable colorectal liver metastases (uCRLM; 100%) and unresectable intrahepatic cholangiocarcinoma (uIHC; 56%). Practice patterns evolved such that uCRLM (94%) and adjuvant therapy for CRLM (adjCRLM; 72%) have become the most common current indications for HAI at established centers. Referral patterns for pump placement differed between uCRLM and uIHC, with most patients referred while receiving second- and first-line therapy, respectively, with physicians preferring to evaluate patients for HAI while receiving first-line therapy for CRLM. Concern for extrahepatic disease was ranked as the most important factor when considering a patient for HAI. Conclusions: Indication and patient selection factors for HAI therapy are relatively uniform across most HCRN centers. The increasing use of adjuvant HAI therapy and overall consistency of practice patterns among HCRN centers provides a robust environment for prospective data collection and randomized clinical trials. © 2023, Society of Surgical Oncology.
Keywords: cancer chemotherapy; medical oncologist; cancer recurrence; liver cell carcinoma; liver cirrhosis; patient selection; cancer adjuvant therapy; cancer patient; antineoplastic agent; clinical practice; treatment indication; questionnaire; physician; bile duct carcinoma; cholangiocarcinoma; inoperable cancer; floxuridine; patient referral; hepatic artery; content analysis; liver fibrosis; hepatic artery infusion; regional therapy; pump; colorectal liver metastasis; human; article; surgical oncologist; multidisciplinary team; colorectal liver metastases (crlm)
Journal Title: Annals of Surgical Oncology
Volume: 30
Issue: 12
ISSN: 1068-9265
Publisher: Springer  
Date Published: 2023-11-01
Start Page: 7362
End Page: 7370
Language: English
DOI: 10.1245/s10434-023-14207-7
PUBMED: 37702903
PROVIDER: scopus
PMCID: PMC11108096
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85171136563&doi=10.1245%2fs10434-023-14207-7&partnerID=40&md5=f6b24ec1b019a37d6626290f8034ebe2
Notes: Article -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Michael D'Angelica
    777 D'Angelica
  2. Nancy Kemeny
    543 Kemeny
  3. Sean James O'Day Judge
    12 Judge
Related MSK Work